Clinical trial NCT02943668 (phase 2, status: terminated)
Conditions: anemia, myelodysplastic syndrome
ICD codes: D53.2, D64.9, D46.4, D53.0, D53.9, D61.3, D61.9, D46.9, D46.C, D46.Z
Drugs: deferasirox
SMILES: CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN
Reason stopped: 
    terminated due to low accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Capable of giving written informed consent prior to any study-specific procedures

          -  Diagnosis of MDS as defined by the World Health Organization (WHO) diagnostic criteria

          -  Have very low, low or intermediate-risk disease by the Revised International
             Prognostic Scoring System (IPSS-R)

          -  Baseline serum ferritin level >= 100 ng/mL

          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

          -  Anemia defined as: hemoglobin =< 10.0 g/dL

          -  Bilirubin =< 1.5 times upper limit of normal (ULN)

          -  Alanine aminotransferase (ALT), and aspartate aminotransferase (AST) =< 3.5 times ULN

          -  Serum creatinine =< 1.5 x ULN

          -  Estimated glomerular filtration rate (GFR) > 40 mL/min

          -  Males and females with reproductive potential must agree to use medically approved
             contraceptive precautions during the study and for 3 months following the last dose of
             deferasirox

               -  Women of child-bearing potential, defined as all women physiologically capable of
                  becoming pregnant, unless they are using effective methods of contraception
                  during dosing of study treatment; effective contraception methods include:

                    -  Placement of an intrauterine device (IUD) or intrauterine system (IUS)

                    -  Barrier methods of contraception: condom or occlusive cap (diaphragm or
                       cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal
                       suppository

                    -  Total abstinence or (when this is in line with the preferred and usual
                       lifestyle of the subject); periodic abstinence (e.g., calendar, ovulation,
                       symptothermal, post-ovulation methods) and withdrawal are not acceptable
                       methods of contraception

                    -  Female sterilization (have had surgical bilateral oophorectomy with or
                       without hysterectomy) or tubal ligation at least six weeks before taking
                       study treatment; in case of oophorectomy alone, only when the reproductive
                       status of the woman has been confirmed by follow up hormone level assessment

                    -  Male sterilization (at least 6 months prior to screening); for female
                       subjects on the study, the vasectomized male partner should be the sole
                       partner for that subject

               -  Women are considered post-menopausal and not of child bearing potential if they
                  have had 12 months of natural (spontaneous) amenorrhea with an appropriate
                  clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have
                  had surgical bilateral oophorectomy (with or without hysterectomy) or tubal
                  ligation at least six weeks ago; in the case of oophorectomy alone, only when the
                  reproductive status of the woman has been confirmed by follow up hormone level
                  assessment is she considered not of child bearing potential; sexually active
                  males must use a condom during intercourse while taking drug and for 28 days
                  after stopping study medication and should not father a child in this period; a
                  condom is required to be used also by vasectomized men in order to prevent
                  delivery of the drug via seminal fluid

          -  Females with childbearing potential* must have had a negative urine or serum pregnancy
             test =< 7 days before the first dose of deferasirox and must also not be breastfeeding

          -  Reliable and willing to make themselves available for the duration of the study and
             are willing to follow study procedures

        Exclusion Criteria:

          -  If the patient is currently receiving erythroid stimulating agents (ESA) with plans to
             continue during study, less than 2 months duration of ESA prior to starting study drug
             and no dose escalation within 2 months of start of study drug

          -  If the patient is being treated with granulocyte-colony stimulating factor (GCSF)
             and/or a TPO-mimetic (for example, eltrombopag or romiplostim) with plans to continue
             during the study: Less than 2 months duration of GCSF or the TPO-mimetic treatment
             prior to starting study drug; or GCSF and/or TPO-mimetic has been added to ESA therapy
             within 2 months of start of study drug

          -  If patient is being treated with lenalidomide with plans to continue during the study:
             Stable dose for less than 3 months prior to start of study drug

          -  If patient is being treated with hypomethylating agents (HMA) (for example,
             azacitidine or decitabine) with plans to continue during the study: Stable dose for
             less than 6 months prior to start of study drug

          -  Currently enrolled in, or discontinued within the last 14 days from a clinical trial
             involving an investigational product or non-approved use of a drug, or concurrently
             enrolled in any other type of medical research judged not to be scientifically or
             medically compatible with this study

          -  Presence of >= 10% blast by morphologic examination of bone marrow aspirate or biopsy

          -  Platelets =< 50,000

          -  Microcytosis on screening blood cell count (CBC) (mean corpuscular volume [MCV] < 81
             fL)

          -  Active gastrointestinal (GI) ulceration or hemorrhage

          -  Have a serious preexisting medical condition that, in the opinion of the investigator
             would preclude participation in the study (for example a GI disorder causing
             clinically significant symptoms such as nausea, vomiting, and diarrhea, or
             malabsorption syndrome) or that would result in a life expectancy of less than 1 year

          -  Known hypersensitivity to deferasirox

          -  History of non-transfusional hemosiderosis

          -  Prior hematopoietic stem cell transplant for the diagnosis of MDS

          -  A second primary malignancy that in the judgment of the principal investigator (PI) or
             designee may affect the interpretation of results

          -  Have an active fungal, bacterial, and/or known viral infection including human
             immunodeficiency virus (HIV) or viral (A, B, or C) hepatitis

          -  Currently using aluminum-containing antacid products

          -  History of clinically significant auditory or ocular toxicity with ICT